Pseudomyxoma peritonei natural history, complications and prognosis: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}{{AE}}{{PSD}} | ||
==Overview== | ==Overview== | ||
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, [[bloating]], [[abdominal distension]], [[weight change]], [[infertility]]. | |||
==Natural History== | ==Natural History== | ||
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, [[bloating]], [[abdominal distension]], [[weight change]], [[infertility]]. | |||
==Prognosis== | ==Prognosis== | ||
Revision as of 15:04, 2 December 2015
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei natural history, complications and prognosis |
|
FDA on Pseudomyxoma peritonei natural history, complications and prognosis |
|
CDC on Pseudomyxoma peritonei natural history, complications and prognosis |
|
Pseudomyxoma peritonei natural history, complications and prognosis in the news |
|
Blogs on Pseudomyxoma peritonei natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, infertility.
Natural History
If left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, infertility.
Prognosis
- Although PMP as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a morbid, recurrent condition with life-threatening complications.[1]
- Biological features of the tumor and access to the current standard of care at specialized oncology centers with a peritoneal surface malignancy program comprise the most important prognostic determinants of PMP.
- Through a retrospective, multi-institutional study on 2298 patients treated at 16 specialized centers affiliated with the Peritoneal Surface Oncology Group International, Chua et al. reported a median survival rate of 196 months (16.3 years) and a median progression-free survival rate of 98 months (8.2 years) as well as 10- and 15-year survival rates of 63% and 59%, respectively.
References
- ↑ Amini, Afshin; Masoumi-Moghaddam, Samar; Ehteda, Anahid; Morris, David (2014). "Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects". Orphanet Journal of Rare Diseases. 9 (1): 71. doi:10.1186/1750-1172-9-71. ISSN 1750-1172.